Atorvastatin News and Research RSS Feed - Atorvastatin News and Research

New controlled drug release system could revolutionize success rate of vascular bypasses

New controlled drug release system could revolutionize success rate of vascular bypasses

Coronary or peripheral bypasses are the most frequently performed vascular operations. Although one million patients per year and around the world, undergo this intervention, its failure rate reaches 50%, because of poor vessel healing, leading to vessel graft occlusion. [More]
Women less likely to stick to cardiac rehabilitation program than men, study finds

Women less likely to stick to cardiac rehabilitation program than men, study finds

Cardiovascular disease is a leading cause of disability globally. Participation in cardiac rehabilitation programs is associated with significantly lower death, but evidence suggests that women are significantly less likely to stick to a cardiac rehabilitation program than men, according to investigators writing in the Canadian Journal of Cardiology. [More]
Evolocumab could be more effective than ezetimibe in lowering cholesterol in statin-intolerant patients

Evolocumab could be more effective than ezetimibe in lowering cholesterol in statin-intolerant patients

In the first major trial of its kind, Cleveland Clinic researchers used a blinded rechallenge with atorvastatin or placebo to objectively confirm the presence of muscle-related symptoms in patients with a history of intolerance to multiple statins and found that evolocumab (a PCSK9 inhibitor) was a more effective option to lower cholesterol than ezetimibe in these patients. [More]
Researchers compare lipid-lowering efficacy for two nonstatin therapies in statin-intolerant patients

Researchers compare lipid-lowering efficacy for two nonstatin therapies in statin-intolerant patients

Steven E. Nissen, M.D., of the Cleveland Clinic, and colleagues identified patients with muscle-related adverse effects from statins and compared lipid-lowering efficacy for two nonstatin therapies, ezetimibe and evolocumab. The study was published online by JAMA, and is being released to coincide with its presentation at the American College of Cardiology's 65th Annual Scientific Session & Expo. [More]
Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in Japan. [More]
Medlab granted ethics approval to begin human trials using nanotechnology delivery platform

Medlab granted ethics approval to begin human trials using nanotechnology delivery platform

Sydney-based, ASX listed, biopharmaceutical company, Medlab Clinical Ltd has been granted ethics approval to progress to two separate human trials using its nanotechnology delivery platform. [More]
Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Resverlogix Corp. is pleased to announce the formation of an international Clinical Steering Committee for the RVX-208 "apabetalone" Phase 3 clinical trial BETonMACE assessing major adverse cardiac events (MACE) in high-risk vascular patients with diabetes mellitus and a recent Acute Coronary Syndrome event. BETonMACE is expected to start in the fall of 2015. [More]
Generic heart disease drugs show promise in patients affected by Ebola virus

Generic heart disease drugs show promise in patients affected by Ebola virus

Generic medications used frequently in the management of heart disease patients also have the potential to bolster the immune systems of patients with Ebola virus and some other life-threatening illnesses, researchers report this week in mBio, the online open-access journal of the American Society for Microbiology. [More]
Statins benefit patients undergoing major lung resection, lower major complications

Statins benefit patients undergoing major lung resection, lower major complications

Statins have been shown to reduce complications from cardiovascular surgery. To determine whether statins might also help those undergoing major lung surgeries, a team at Memorial Sloan Kettering Cancer Center conducted a well-designed study that randomized patients to receive either a statin or placebo before and after surgery. [More]
New study predicts outcomes of CV patients using polypill intervention

New study predicts outcomes of CV patients using polypill intervention

A new study published in the journal BMJ Open (May 2015) has demonstrated that the improved treatment adherence achievable using a fixed-dose combination polypill (atorvastatin, ramipril and low-dose aspirin) to prevent recurring myocardial infarction, can avoid up to 15% more fatal and non-fatal CV events, conferring potential savings to healthcare systems. [More]
Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. [More]
Australian Prescriber publishes top 10 subsidised drugs in Australia

Australian Prescriber publishes top 10 subsidised drugs in Australia

The annual publication of the top 10 subsidised drugs appears in the December edition of Australian Prescriber. Statins (cholesterol-lowering medicines) top the lists again. [More]
Researchers to study effectiveness of atorvastatin in preventing heart problems in breast cancer patients

Researchers to study effectiveness of atorvastatin in preventing heart problems in breast cancer patients

Wake Forest Baptist Medical Center has been awarded $4.4 million to conduct a multiple-site clinical trial testing the effectiveness of a statin drug in preventing cardiovascular events in women treated for breast cancer. [More]
Commonly used lipid-lowering drug protects against cerebral ischemia/reperfusion injury

Commonly used lipid-lowering drug protects against cerebral ischemia/reperfusion injury

In addition to its lipid-lowering effect, statins exert anti-inflammatory and antioxidant effects as well. [More]
Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc. [More]
Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Lipids, primarily cholesterol and triglycerides, come from two sources: what is naturally manufactured in the liver and what comes from the intestines through the diet. [More]
Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to placebo in patients with high cholesterol. [More]
Dr. Reddy's Laboratories launches Amlodipine Besylate and Atorvastatin Calcium Tablets

Dr. Reddy's Laboratories launches Amlodipine Besylate and Atorvastatin Calcium Tablets

Dr. Reddy's Laboratories announced today that it has launched Amlodipine Besylate and Atorvastatin Calcium Tablets 2.5/10mg, 2.5/20mg, 2.5/40mg, 5/10mg, 5/20mg, 5/40mg, 5/80mg, 10/10mg, 10/20mg, 10/40mg and 10/80 mg a therapeutic equivalent generic version of CADUET (amlodipine Besylate and atorvastatin calcium) tablets, in the US market on March 26, 2014, following the approval by the United States Food & Drug Administration. [More]
Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use. [More]
High-potency statins offer improved chance of survival in heart attack patients

High-potency statins offer improved chance of survival in heart attack patients

A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment with high-potency statins offers a significantly improved chance of survival compared to those taking normal statins. [More]
Advertisement
Advertisement